Assenagon Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-198,846
| Closed | -$511K | – | 1463 |
|
|
2024
Q2 | $511K | Hold |
198,846
| – | – | ﹤0.01% | 1206 |
|
|
2024
Q1 | $978K | Hold |
198,846
| – | – | ﹤0.01% | 1037 |
|
|
2023
Q4 | $1.75M | Sell |
198,846
-215,209
| -52% | -$1.89M | ﹤0.01% | 941 |
|
|
2023
Q3 | $4.75M | Buy |
+414,055
| New | +$4.75M | 0.01% | 568 |
|
|
2023
Q2 | – | Sell |
-194,911
| Closed | -$6.28M | – | 1450 |
|
|
2023
Q1 | $6.28M | Buy |
194,911
+2,552
| +1% | +$82.2K | 0.02% | 494 |
|
|
2022
Q4 | $3.55M | Sell |
192,359
-383,205
| -67% | -$7.07M | 0.01% | 593 |
|
|
2022
Q3 | $15.5M | Buy |
575,564
+444,916
| +341% | +$12M | 0.06% | 254 |
|
|
2022
Q2 | $1.81M | Buy |
130,648
+8,389
| +7% | +$116K | 0.01% | 844 |
|
|
2022
Q1 | $2.38M | Buy |
122,259
+3,395
| +3% | +$66.2K | 0.01% | 738 |
|
|
2021
Q4 | $1.94M | Buy |
+118,864
| New | +$1.94M | 0.01% | 797 |
|
|
2021
Q3 | – | Sell |
-141,825
| Closed | -$4.2M | – | 1417 |
|
|
2021
Q2 | $4.2M | Buy |
+141,825
| New | +$4.2M | 0.01% | 491 |
|
|
2020
Q2 | – | Sell |
-16,375
| Closed | -$242K | – | 1222 |
|
|
2020
Q1 | $242K | Buy |
+16,375
| New | +$242K | ﹤0.01% | 675 |
|